Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Significance Statement: Kidney toxicity from use of immune checkpoint inhibitors is being recognized as an increasingly frequent complication of treatment. However, existing data on immune checkpoint inhibitor–associated AKI have been limited to small, mostly single-center studies. In this multicenter study of 138 patients with immune checkpoint inhibitor–associated AKI and 276 controls, the authors characterize the clinical features of this complication and identify risk factors associated with its development, clinicopathologic features, and determinants of kidney recovery after an episode. Failure to achieve kidney recovery was associated with worse overall survival, and a minority (23%) of patients who were retreated with immune checkpoint inhibitors had a recurrence of AKI. The study provides insights into immune checkpoint inhibitor–associated AKI, although further study is needed to inform the care of affected patients. Background: Despite increasing recognition of the importance of immune checkpoint inhibitor–associated AKI, data on this complication of immunotherapy are sparse. Methods: We conducted a multicenter study of 138 patients with immune checkpoint inhibitor–associated AKI, defined as a ≥2-fold increase in serum creatinine or new dialysis requirement directly attributed to an immune checkpoint inhibitor. We also collected data on 276 control patients who received these drugs but did not develop AKI. Results: Lower baseline eGFR, proton pump inhibitor use, and combination immune checkpoint inhibitor therapy were each independently associated with an increased risk of immune checkpoint inhibitor–associated AKI. Median (interquartile range) time from immune checkpoint inhibitor initiation to AKI was 14 (6–37) weeks. Most patients had subnephrotic proteinuria, and approximately half had pyuria. Extrarenal immune-related adverse events occurred in 43% of patients; 69% were concurrently receiving a potential tubulointerstitial nephritis–causing medication. Tubulointerstitial nephritis was the dominant lesion in 93% of the 60 patients biopsied. Most patients (86%) were treated with steroids. Complete, partial, or no kidney recovery occurred in 40%, 45%, and 15% of patients, respectively. Concomitant extrarenal immune-related adverse events were associated with worse renal prognosis, whereas concomitant tubulointerstitial nephritis–causing medications and treatment with steroids were each associated with improved renal prognosis. Failure to achieve kidney recovery after immune checkpoint inhibitor–associated AKI was independently associated with higher mortality. Immune checkpoint inhibitor rechallenge occurred in 22% of patients, of whom 23% developed recurrent associated AKI. Conclusions: This multicenter study identifies insights into the risk factors, clinical features, histopathologic findings, and renal and overall outcomes in patients with immune checkpoint inhibitor–associated AKI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.1 · Cited by 4,326
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · cited 1×
“44 Required RRT at GC initiation, n (%) 3 (3) 1 (2) 2 (3) 0.”
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · cited 1×
“64 Autoimmune disease, n (%) 2 (6) 0 (0) 2 (8) 0.”
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · cited 1×
“36 Combo anti–CTLA-4+anti–PD-1/PD-L1 39 (28) 35 (13) ,0.”
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650 · cited 1×
“15 White 116 (84) 248 (91) Black 10 (7) 10 (4) Asian 3 (2) 5 (2) Comorbidities, n (%) Hypertension 77 (56) 171 (62) 0.”
Self-citationDiagnosis, Epidemiology and Outcomes of Acute Kidney Injury
Waikar, S. S., Liu, K. D., & Chertow, G. M. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05191107 · Cited by 533 · cited 1×
“36 Combo anti–CTLA-4+anti–PD-1/PD-L1 39 (28) 35 (13) ,0.”
González, E., Gutiérrez, E., Galeano, C., Chevia, C., de Sequera, P., Bernis, C., Parra, E. G., Delgado, R., Sanz, M., Ortiz, M., et al. (2008) · Kidney International · doi:10.1038/sj.ki.5002776 · Cited by 466
Schadendorf, D., Wolchok, J. D., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Chesney, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2289 · Cited by 441
Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00005 · Cited by 377
Acute interstitial nephritis: clinical features and response to corticosteroid therapy
Clarkson, M. R. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh485 · Cited by 343 · cited 1×
“007 Melanoma 49 (36) 82 (30) Lung 36 (26) 106 (38) Genitourinary 23 (17) 21 (8) Other 30 (21) 67 (24) PPI, n (%) 75 (54) 92 (33) ,0.”
Biopsy-proven acute interstitial nephritis, 1993-2011: a case series
Muriithi, A. K., Leung, N., Valeri, A. M., Cornell, L. D., Sethi, S., Fidler, M. E., & Nasr, S. H. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.04.027 · Cited by 337
Association between AKI, Recovery of Renal Function, and Long-Term Outcomes after Hospital Discharge
Pannu, N., James, M., Hemmelgarn, B., & Klarenbach, S. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06480612 · Cited by 302
Mamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A., Gaber, L., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 296
Self-citationShirali, A. C., Perazella, M. A., & Gettinger, S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.02.057 · Cited by 284 · cited 3×
“96 Received non-GC immunosuppressant, n (%) 11 (9) 4 (8) 7 (11) 0.”
Self-citationBlank, M.-L., Parkin, L., Paul, C., & Herbison, P. (2014) · Kidney International · doi:10.1038/ki.2014.74 · Cited by 213
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Perazella, M. A., & Shirali, A. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050488 · Cited by 162
Self-citationKitchlu, A., McArthur, E., Amir, E., Booth, C. M., Sutradhar, R., Majeed, H., Nash, D. M., Silver, S. A., Garg, A. X., Chan, C. T., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy167 · Cited by 160
Self-citationKinetic eGFR and Novel AKI Biomarkers to Predict Renal Recovery
Dewitte, A., Joannès-Boyau, O., Sidobre, C., Fleureau, C., Bats, M., Derache, P., Leuillet, S., Ripoche, J., Combe, C., & Ouattara, A. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12651214 · Cited by 134 · cited 2×
“001 Autoimmune disease, n (%) 17 (12) 30 (11) 0.”
Chronic Kidney Disease: An Inherent Risk Factor for Acute Kidney Injury?
Singh, P., Rifkin, D. E., & Blantz, R. C. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00830110 · Cited by 133 · cited 1×
“29 Female, n (%) 8 (26) 1 (14) 7 (29) 0.”
Fernandez-Juarez, G., Perez, J. V., Caravaca-Fontán, F., Quintana, L., Shabaka, A., Rodriguez, E., Gadola, L., de Lorenzo, A., Cobo, M. A., Oliet, A., et al. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01390118 · Cited by 133
Renal toxicities associated with pembrolizumab
Izzedine, H., Mathian, A., Champiat, S., Picard, C., Mateus, C., Routier, É., Varga, A., Malka, D., Leary, A. F., Michels, J., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy100 · Cited by 133 · cited 1×
“001 Autoimmune disease, n (%) 17 (12) 30 (11) 0.”
Proton pump inhibitors and the kidney: critical review
Brewster, U. C., & Perazella, M. A. (2007) · Clinical Nephrology · doi:10.5414/cnp68065 · Cited by 129
Koda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., Imai, N., & Narita, I. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0848-y · Cited by 77
AKI in Patients Receiving Immune Checkpoint Inhibitors
Perazella, M. A., & Sprangers, B. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02340219 · Cited by 52
Research works printed but not linked: 1
- Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. : Kidney disease: Improving Global Outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2: 1–138, 2012 [Google Scholar]
Cited by
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,311
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Self-citationBrahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Self-citationChennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J., & Manne, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.779691 · Cited by 344
Acute kidney injury in patients treated with immune checkpoint inhibitors
Gupta, S., Short, S. A. P., Sise, M. E., Prosek, J. M., Madhavan, S. M., Soler, M. J., Ostermann, M., Herrmann, S. M., Abudayyeh, A., Anand, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003467 · Cited by 236
Self-citation
Metadata
- Authors
- Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., Abudayyeh, A., Mamlouk, O., Motwani, S. S., Murakami, N., Herrmann, S. M., Manohar, S., Shirali, A. C., Kitchlu, A., Shirazian, S., Assal, A., Vijayan, A., Renaghan, A. D., Ortiz-Melo, D. I., Rangarajan, S., Malik, A. B., Hogan, J. J., Dinh, A. R., Shin, D. S., Marrone, K. A., Mithani, Z., Johnson, D. B., Hosseini, A., Uprety, D., Sharma, S., Gupta, S., Reynolds, K. L., Sise, M. E., & Leaf, D. E.
- Affiliations
- Massachusetts General Hospital (US)
- Division of Renal Medicine, Brigham and Women’s Hospital, Boston, Massachusetts;
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Yale University (US)
- University Health Network (CA)
- Division of Nephrology and
- Columbia University Irving Medical Center (US)
- Washington University in St. Louis (US)
- University of Virginia Medical Center (US)
- Duke Medical Center (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- Johns Hopkins University (US)
- University of Miami (US)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Cortazar, Frank B.
- ORCID
- Cortazar, Frank B.
- Glezerman, Ilya G.
- Abudayyeh, Ala
- Mamlouk, Omar
- Motwani, Shveta S.
- Murakami, Naoka
- Herrmann, Sandra M.
- Manohar, Sandhya
- Shirali, Anushree C.
- Kitchlu, Abhijat
- Shirazian, Shayan
- Assal, Amer
- Vijayan, Anitha
- Renaghan, Amanda DeMauro
- Ortiz-Melo, David I.
- Rangarajan, Sunil
- Hogan, Jonathan J.
- Dinh, Alex R.
- Shin, Daniel Sanghoon
- Marrone, Kristen A.
- Johnson, Douglas B.
- Sharma, Shreyak
- Gupta, Shruti
- Reynolds, Kerry L.
- Sise, Meghan E.
- Leaf, David E.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2020-01-02
- Volume
- 31
- Issue
- 2
- Pages
- 435-446
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC7003302
- OpenAlex
- W2997561837
- Cited by
- 407
- References
- 31
- Citations by year
- 2026: 54 · 2025: 48 · 2024: 57 · 2023: 60 · 2022: 77 · 2021: 62 · 2020: 48
- FWCI
- 22.30
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK120868)
- American Society of Nephrology
- NIDDK (K08DK118120, K23DK117014, K23DK106448)
- National Heart, Lung, and Blood Institute (R01HL144566)
- ASN
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Keywords
- acute kidney injury, immune checkpoint inhibitors, immunotherapy adverse events, interstitial nephritis, risk factors, renal function recovery, overall survival, immune-related adverse events, corticosteroid therapy, immune checkpoint inhibitor rechallenge, renal prognosis, proton pump inhibitors, EGFR, proteinuria, pyuria
- MeSH terms
- Aged, Female, Humans, Kidney, Male, Middle Aged, Nephritis, Interstitial, Retrospective Studies, Risk Factors, Acute Kidney Injury, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.